Enhancing activity of Pleurotus sajor-caju (Fr.) Sing β-1,3-Glucanoligosaccharide (Ps-GOS) on proliferation, differentiation, and mineralization of MC3T3-E1 cells through the involvement of BMP-2/Runx2/MAPK/Wnt/β-catenin signaling pathway by Yodthong, T. et al.
This is a repository copy of Enhancing activity of Pleurotus sajor-caju (Fr.) Sing 
β-1,3-Glucanoligosaccharide (Ps-GOS) on proliferation, differentiation, and mineralization 
of MC3T3-E1 cells through the involvement of BMP-2/Runx2/MAPK/Wnt/β-catenin 
signaling pathway.
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/157430/
Version: Published Version
Article:
Yodthong, T., Kedjarune-Leggat, U., Smythe, C. orcid.org/0000-0001-6526-0565 et al. (4 
more authors) (2020) Enhancing activity of Pleurotus sajor-caju (Fr.) Sing 
β-1,3-Glucanoligosaccharide (Ps-GOS) on proliferation, differentiation, and mineralization 
of MC3T3-E1 cells through the involvement of BMP-2/Runx2/MAPK/Wnt/β-catenin 
signaling pathway. Biomolecules, 10 (2). 190. 
https://doi.org/10.3390/biom10020190
eprints@whiterose.ac.uk
https://eprints.whiterose.ac.uk/
Reuse 
This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence 
allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the 
authors for the original work. More information and the full terms of the licence here: 
https://creativecommons.org/licenses/ 
Takedown 
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by 
emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request. 
biomolecules
Article
Enhancing Activity of Pleurotus sajor-caju (Fr.) Sing
β-1,3-Glucanoligosaccharide (Ps-GOS) on
Proliferation, Differentiation, and Mineralization of
MC3T3-E1 Cells through the Involvement of
BMP-2/Runx2/MAPK/Wnt/β-Catenin
Signaling Pathway
Thanintorn Yodthong 1, Ureporn Kedjarune-Leggat 2 , Carl Smythe 3 , Pannawich Sukprasirt 4,
Aratee Aroonkesorn 1, Rapepun Wititsuwannakul 4 and Thanawat Pitakpornpreecha 1,4,*
1 Department of Biochemistry, Faculty of Science, Prince of Songkla University, Hat-Yai, Songkhla 90112,
Thailand; thanintorn.y@gmail.com (T.Y.); aratee.a@psu.ac.th (A.A.)
2 Department of Oral Biology and Occlusion, Faculty of Dentistry, Prince of Songkla University, Hat-Yai,
Songkhla 90112, Thailand; ureporn.l@psu.ac.th
3 Department of Biomedical Science, University of Sheffield, Sheffield S10 2TN, UK;
c.g.w.smythe@sheffield.ac.uk
4 Center of Excellence in Natural Rubber Latex Biotechnology Research and Development, Prince of Songkla
University, Hat-Yai, Songkhla 90112, Thailand; nutideal@hotmail.com (P.S.); wrapepun@yahoo.com (R.W.)
* Correspondence: thanawat.psu@gmail.com or thanawat.p@psu.ac.th; Tel.: +66-742-882-65
Received: 9 January 2020; Accepted: 24 January 2020; Published: 27 January 2020


Abstract: Osteoporosis is a leading world health problem that results from an imbalance between
bone formation and bone resorption. β-glucans has been extensively reported to exhibit a wide
range of biological activities, including antiosteoporosis both in vitro and in vivo. However, the
molecular mechanisms responsible for β-glucan-mediated bone formation in osteoblasts have not
yet been investigated. The oyster mushroom Pleurotus sajor-caju produces abundant amounts of an
insoluble β-glucan, which is rendered soluble by enzymatic degradation using Hevea glucanase to
generate low-molecular-weight glucanoligosaccharide (Ps-GOS). This study aimed to investigate the
osteogenic enhancing activity and underliningmolecular mechanism of Ps-GOS on osteoblastogenesis
of pre-osteoblastic MC3T3-E1 cells. In this study, it was demonstrated for the first time that low
concentrations of Ps-GOS could promote cell proliferation and division after 48 h of treatment.
In addition, Ps-GOS upregulated the mRNA and protein expression level of bone morphogenetic
protein-2 (BMP-2) and runt-related transcription factor-2 (Runx2), which are both involved in BMP
signaling pathway, accompanied by increased alkaline phosphatase (ALP) activity and mineralization.
Ps-GOS also upregulated the expression of osteogenesis related genes including ALP, collagen type
1 (COL1), and osteocalcin (OCN). Moreover, our novel findings suggest that Ps-GOS may exert its
effects through the mitogen-activated protein kinase (MAPK) and wingless-type MMTV integration
site (Wnt)/β-catenin signaling pathways.
Keywords: glucanoligosaccharide; pleurotus sajor-caju; osteoblastogenesis; β-1,3-glucanase
1. Introduction
Osteoporosis is a global disease resulting from an imbalance of bone homeostasis. An increase
in the ratio of bone resorption to bone formation causes low bone mass and strength, which leads
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to increased fragility and susceptibility to fracture [1]. The disease occurs in older (>50 year) men
and women [2], with increased likelihood in post-menopausal women. The latter effect is due to the
absence of estrogen [3], which plays a crucial role in maintaining bone metabolic balance in bone
homeostasis [4,5].
Bone remodeling is a continuous process regulated by two major types of bone cell. Osteoclasts
mediate bone resorption to remove small pieces of bone fractures, and osteoblasts mediate bone
formation to form new bone tissue [6]. An imbalance involving an increase in bone resorption and/or a
decrease in bone formation can cause osteoporosis [7].
Osteoblastogenesis—the process of osteoblast proliferation and differentiation contributing to
bone strength and rigidity [8]—is regulated by several signal transduction pathways, including the
bone morphogenetic protein (BMP) signaling pathway. BMP-2, one of the most important growth
factors in the BMP subfamily, plays an important role by regulating the downstream osteogenic
runt-related transcription factor2 (Runx2) [9]. The function of Runx2 is to promote the early stage
of osteoblastogenesis, by triggering the expression of bone matrix genes and calcium deposition for
mineralization [10]. As inhibition of BMP-2 activity is known to result in a loss of induction of the
osteoblast differentiation marker Alkaline Phosphatase (ALP) [11], it follows that BMP-2 is a potential
target to seek alternative novel molecular entities that promote bone formation.
In addition to the BMP signaling pathway, both mitogen-activated protein kinase (MAPK)
and wingless-type MMTV integration site (Wnt)/β-catenin signaling pathways are involved in the
progression of bone remodeling via osteoblast differentiation [12]. MAPK family members extracellular
signal regulated-kinases (ERKs), c-Jun N-terminal kinases (JNKs), and p38 kinaseperform essential
functions in many mammalian cells, including osteoblasts, by controlling proliferation, differentiation,
anddevelopment [13]. Additionally,Wnt/β-catenin signaling is required for pre-osteoblast proliferation,
osteoblastogenesis, and inhibition of osteoblast apoptosis [14,15]. In vivo deletion of β-catenin causes
a reduction in bone formation and the induction of ostoclastogenesis [16].
While there are many therapeutics in use for osteoporosis treatment, there are significant risks
associatedwith them. Long-termuse of antiosteoporotic drugs such as estrogen replacement therapy are
associatedwith breast cancer and ovarian cancer [17,18], while bisphosphonates can cause osteonecrosis
of the jaw [19]. It follows there is a unmet need for new agents, with fewer side effects, that can promote
bone formation.
Various types of naturally-derived compounds, including glycosides, flavonoids, terpenoids,
coumarins, phenols, and phenolates, have been reported to restore bone homeostasis via a range
of cellular mechanisms, including the modulation of transcription factors, bone-specific protein,
signal pathways, and the OPG/RANKL system [20]. β-Glucans, glucose polymers containing a
β-glycosidic link, are derived from natural dietary fiber and are potential candidates for the treatment
or prevention of osteoporosis. Numerous β-glucans, with varying degrees of polymerization and
branching, including β-1→3-, β-1→4-, β-1→6-, β-1→3/1→4-, and β-1→3/1→6-linkages, are found in a
variety of natural sources including cereals, fungi, yeast, bacteria, and algae [21]. β-glucans have been
extensively studied, and a wide range of biological activities have been reported, including immune
enhancement [22] as well as antitumor, anti-aging, antihypocholesterolemic, antihyperglycemic [23],
and antiinflammation activity [24]. Moreover, antiosteoporosis activity has also been reported both
in vitro and in vivo [25]. For example, β-glucan extracted from P. citrinopileatuswas shown to inhibit
RANKL-induced osteoclast differentiation [25]. In addition, β-(1,3)-(1, 6)-glucan extracted from
Aureobasidium pullulans had a stimulatory effect on BMP-7-associated osteoblast differentiation [26]
and the suppression of bone loss in an ovariectomy-induced osteoporosis rat, an animal model for
post-menopausal osteoporosis [27]. Nevertheless, the molecular mechanisms by which β-glucans
promote bone formation in osteoblasts have not yet been investigated.
Here, we wished to investigate the enhancing activity and underpinning molecular mechanisms
of a β-glucan, extracted from the popular edible grey oyster mushroom, Pleurotus sajor-caju [28], on
osteoblastogenesis. This mushroom has been widly used in traditional medicine and reported
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to posseses various biological activities, including antimicroorganisms, antitumor, antioxidant,
antihypertension, antidiabetic, and anti-inflammation. According to its various biological activities,
many biologically active compounds have also been studied regarding its role on therapeutic
applications such as β-glucans, proteoglycan, phenolic acids, terpenes, proteins, and sterols [29].
Extracted Pleurotus sajor-caju β-glucan has a high molecular weight and low water solubility. The
biological activities ofβ-glucans usually depend on physicochemical properties, source, purity, primary
structure, water solubility, and molecular weight [30,31]. Insoluble particulate β-glucans have limited
potential for medicinal applications, but may have more applicability following partial hydrolysis. For
example, curdlan, which is a water-insoluble microbial linear exo-polysaccharide (1→3) β-d-glucan,
has recently been effectively digested with a novel recombinant endo-β-1→3-glucanase to obtain a
water soluble glucanoligosaccharide [32]. Here, we have used Hevea β-1,3-glucanase isozymes GI
and GII, previously reported to specifically hydrolyse glucans such as laminarin [33], containing a
low frequency of β-1,3-d-glucosidic linkages. We have digested particulate β-glucans to obtain a
hydrolysate, Pleurotus sajor-caju glucanoligosaccharide (Ps-GOS), with shorter chain length, lower
molecular weight, and higher water solubility (Ratthajak et al., manuscript in preparation).
The aim of this study is to investigate the effect of Ps-GOS on the proliferation and differentiation
of the murine pre-osteoblastic cell line MC3T3-E1. We show that Ps-GOS promotes MC3T3-E1 cell
proliferation, and induction of BMP-2 and Runx-2, which act coordinately, together with components
of MAPK and Wnt/β-catenin signaling pathways, to enhance both gene expression of osteogenic bone
markers and mineralization.
2. Materials and Methods
2.1. Materials
Alpha modification of Eagle’s minimum essential medium (α-MEM), fetal bovine serum
(FBS), RPMI-1640 phenol red-free medium, and tissue culture reagents were purchased
from Gibco (Grand Island, NY, USA). β-glycerophosphate, l-ascorbic acid, and MTT
(3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) were purchased from Sigma Aldrich
(St. Louis, MO, USA). All specific primers were synthesized from Sigma Aldrich (St. Louis, MO, USA).
All other reagents and chemicals were the grade quality available.
2.2. Preparation of Water Soluble P. sajor-caju Glucanoligosaccharide (Ps-GOS)
Ps-GOS was obtained from an investigation under the Center of Excellence in Natural Rubber
Latex Biotechnology Research and Development (CERB) (additional details are under patent and will
be published elsewhere). Briefly, the insoluble β-glucan fraction was isolated from the fruiting bodies
of grey oyster mushroom (Pleurotus sajor-caju) according to modified Freimund’s method [34,35].
The β-glucan assay was conducted according to the method of McClear and Glennie-Holmes [36],
using the Mushroom and Yeast β-glucan kit (K-YBGL) (Megazyme International Ireland Ltd., Wicklow,
Ire-land). The soluble β-glucan from P. sajor-caju (Ps-GOS) was prepared by mixing the insoluble
β-glucan (mean particle size as 646.6 ± 299.3 µm determined using a Beckman Coulter LS 230 Laser
Diffraction Particle Size Analyser) with the concentrate enzyme fraction contained 0.66 nkat ml−1 of
glucanase activity (ratio of 1.5%, w/v). The optimized Hevea glucanase conditions of the concentrate
enzyme fraction were chosen according to report of Churngchow et al., [33]. After complete digestion,
the Ps-GOS derived after centrifugation was freeze-dried (mean particle size as 122.7 ± 147.0 µm). Both
insoluble β-glucan and Ps-GOS were subjected to FTIR spectroscopy for structural characterization
(data not shown). Data from electrospray ionization mass spectrometry (ESI-MS) demonstrated the
mass of insoluble β-glucan, and Ps-GOS was distributed from 20 and 5 kDa, respectively.
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2.3. Culture and Differentiation
The murine pre-osteoblast cell line, MC3T3-E1 (subclone 14 CRL-2593), was obtained from
American Tissue Culture Collection (ATCC, Manassas, VA, USA). MC3T3-E1 cells were cultured in
α-MEMcontaining 10%FBSwith 1%penicillin/streptomycin solution (penicillin 100U/mL, streptomycin
100 U/mL) at 37 ◦C in a 5% CO2 incubator (Thermo Fisher Scientific, Waltham, MA, USA). The culture
medium was changed every 2–3 days, and cells of a passage number 23 were used for all experiments.
To induce osteoblast differentiation, cells were cultured in osteogenic induction medium containing 50
µg/mL l-ascorbic acid and 1 M β-glycerophosphate.
2.4. Cell Proliferation
MTT assay was performed as an indicator for cell proliferation based on the ability of cells to
convert MTT into a formazan reaction product. MC3T3-E1 cells were seeded and then treated with
Ps-GOS at various concentrations for 24 and 48 h. At the end of treatment, cultured cells were washed
with PBS. Next, 5 mg/mL of MTT and RPMI-1640 phenol red-free medium were added and incubated
at 37 ◦C. After 3 h, the mixture was removed and the formazan product was solubilized by acidic
isopropanol. The absorbance was measured by microplate reader at 570 nm.
2.5. Alkaline Phosphatase (ALP) Activity Assay
Cells were seeded in 24 well plates and then treated with different concentrations of Ps-GOS
for 14 days. After treatment, the cells were washed with PBS and lysed with lysis buffer containing
50 mM Tris-HCL (pH 7.4) and 1% Triton X-100 to collect supernatant for determining ALP activity
and protein concentration. ALP activity was determined with 4 mg/mL of 4-nitrophenyl phosphate
(4NPP) in 0.2 M of 2-amino-2-methyl-1-propanol with 4 mM of MgCl2 as a substrate for 30 min at
37 ◦C. The reaction was stopped by 0.1 M NaOH, and the yellow solution was measured at 405 nm.
Protein concentration was measured using the Pierce BCA Protein Assay Kit (ThermoFisher Scientific,
Waltham, MA, USA). ALP activity was normalized to the concentration of protein and showed in the
term of µmole/min/mg of protein.
2.6. Alizarin Red S Staining
Alizarin red S staining was used to determine calcium accumulation. In brief, cells were grown in
24 well plates and treated with Ps-GOS for 14 and 21 days. After incubation, cells were washed with
PBS and then fixed with 10% formaldehyde 15 min. The cells were stained with 40 mM Alizarin red S
solution (pH 4.1–4.3) for 30 min with gentle shaking at the room temperature. To quantify the dye,
nonspecific staining was removed by washing with distilled water five times (5 min/time) and then
solubilizing the stain with cetylpyridinium chloride (CPC) by shaking, and the absorbance at 550 nm
was measured.
2.7. Cell Cycle Analysis
Cell cycle assay was performed by flow cytometry to analyze the cell cycle progression while
treating with Ps-GOS for 48 h. Cells were trypsinized and fixed in 70% ethanol at 4 ◦C for 30 min,
followed by incubation with propidium iodide containing RNase staining solution (Merck, Branchburg,
NJ, USA) for 30 min in the dark to detect DNA content in the cells. The percentage of cells in G0/G1, S,
and G2/M phases was analyzed by flow cytometry Guava easyCyteTM HT (Hayward, CA, USA).
2.8. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
Total RNA from growing cells incubated with Ps-GOS for 24, 48, and 72 h was extract using the
TriPure Isolation Reagent (Roche, Buonas, Switzerland). To generate cDNA, total RNA (1 µg) was used
as a template to transcribe into cDNA using the Transcriptor First Strand cDNA Synthesis Kit (Roche,
Buonas, Switzerland) according to the manufacturer’s instruction. This cDNA was used to determine
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the gene expression for the genes of interest using the gene specific primers detailed in Yodthong’s
study [37] and GAPDH as the house keeping control gene. qRT-PCR reactions were amplified using the
EvaGreen HRMMix (Solis Biodyne, Tartu, Estonia), and then relative expression ratio was calculated
using the 2−∆∆Ct method.
2.9. Western Blot Analysis
Cells were grown and treated with Ps-GOS in six well plates. After indicated time, the cells were
lyzed with lysis buffer and then centrifuged at 14,000× g for 15 min at 4 ◦C to collect supernatant
for using as total protein extract. The concentration of protein was quantified using a protein assay
kit (Bio-Rad, Hercules, CA, USA). Equal amounts of protein from each sample were loaded onto
10% gels for SDS-PAGE, transferred to nitrocellulose membranes (Amersham Pharmacia Biotech,
Amersham Buckinghamshire, UK), blocked with 5% nonfat dry milk solution for 1 h, and then
incubated with antiBMP-2 (Abcam, Milton, UK), antiRunx2 (Cell Signaling Technology, Beverly, MA,
USA), or antiβ-Actin (Sigma-Aldrich, St. Louis, MO, USA). After washing three times with TBS-Tween,
the blots were probedwith an Alexa infrared dye-conjugated secondary antibody (Invitrogen, Carlsbad,
CA, USA) for 1 h and detected the bands by Odyssey Infrared Imaging System (LI-CORE) in accordance
with the manufacturer’s instruction. The relative of the intensity of the protein interesting bands and
the intensity of β-Actin band were compared.
2.10. Immunofluorescence Microscopy
The cells treated with Ps-GOS were grown on sterile collagen-coated coverslips in 24 well plates.
In brief, coverslips were fixed with 4% paraformaldehyde 20 min, quenched with 50 mM NH4Cl
for 2 × 10 min, washed with PBS, and permeabilized with 0.1% Triton X-100 for 10 min at RT. After
blocking with 0.5% FSG in PBS for 20 min, each coverslip was incubated overnight at 4 ◦C with
polyclonal rabbit antimouse BMP-2 (Abcam, Milton, UK), followed by removing primary antibody
and washing 3 × 5 min in blocking solution before incubation for 1 h with FITC-conjugated secondary
antirabbit IgG (Alexa Fluor 680) (Thermo Fisher Scientific, Waltham, MA, USA) and DAPI counterstain
(Thermo Fisher Scientific, Waltham, MA, USA). Coverslips were washed 3 × 5 min in blocking solution
and mounted on to slides using ProlongTM Gold antifade reagent (Invitrogen, Carlsbad, CA, USA).
Fluorescence images were acquired with Nikon Eclipse Ti fluorescence microscope.
2.11. Statistical Analysis
Representative data are presented as the mean ± standard error of the mean (SEM). Statistical
analysis was performed using the SPSS 23 statistical software (SPSS Inc., Chicago, IL, USA). The
significant results were analyzed by one-way analysis of variance (ANOVA), followed by Duncan’s
multiple range test. Different significances are indicated (* = p < 0.05, ** = p < 0.01).
3. Results
3.1. Effect of Ps-GOS on Proliferation of MC3T3-E1 Cells
To determine the dose dependence of Ps-GOS on proliferation, MTT assays were used to measure
the metabolic activity of osteoblastic cells during proliferation. MC3T3-E1 cells were treated with
0.001–1000 µg/mL of Ps-GOS for 24–72 h (Figure 1). Compared to control (cells without treatment),
exposure to Ps-GOS for 48 h significantly increased cell proliferation at concentrations up to 10 µg/mL
(p < 0.05) by 48 h, although proliferation was reduced at all concentrations after 72 h. Ps-GOS appeared
to have a cytotoxic effect at higher concentrations (100 and 1000 µg/mL (p < 0.01)) after treatment
for 72 h. Subsequently, only concentrations in the range 0.001 to 10 µg/mL were used in further
experiments. This results indicated that low concentrations of Ps-GOS stimulate osteoblast proliferation
without toxicity.
Biomolecules 2020, 10, 190 6 of 16
	
 ==
>+ L

"****P"9

	
,




'D1 

	







	!

,"
"
.
'D1 /
	

E6272'7





'D1 +55?>+6	


E,,, 	"

% 
% 
.**R%


/7	
		

	O 7EW**@W**	
&9
 $''.(
	'&5&9'

	  
%
" 
'D1  	"

6
#
"30	
"
	

	"D*D D+E0
%	

"





'D1  5? 0
" 
 .*P"9/
'D1 

"

		

D*D	



"

  	  	    .
" +/ ,
    
'D1  
		


"	"

 	D

Figure 1. The effect of glucanoligosaccharide (Ps-GOS) on osteoblastic cell proliferation. MC3E3-E1
cells were treated with the indicated concentrations of Ps-GOS for 24, 48, and 72 h. Cell proliferation
was measured by MTT assay. The result shows percentage of metabolically active cells relative to
untreated cells (control = 100% viability). Each point of data represents the means of four replicate
samples ± SEM. * = p < 0.05, ** = p < 0.01 when compared to the control.
3.2. Effect of Ps-GOS on Cell Cycle Distribution on MC3T3-E1 Cells
Flow cytometry was performed to investigate the effect of Ps-GOS on cell cycle progression.
Cell cycle analysis was undertaken by measuring cellular DNA content corresponding to each of the
three principle cell cycle stages; G0/G1, S, and G2/M. Actively proliferating cells were treated with
indicated concentrations of Ps-GOS for 48 h. At higher concentrations (1 and 10 µg/mL), Ps-GOS
significantly decreased the proportion of cells in G0/G1 phase while concomitantly increasing that in S
phase when compared to control cells (Figure 2). This study demonstrates that Ps-GOS can promote
cell proliferation by accelerating progression into S phase from G1.
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Figure 2. The effect of Ps-GOS on the division of cell. (A) A pictorial graph shows the result from flow
cytometry analysis after osteoblastic cells were treated with the different concentrations of Ps-GOS for
48 h. (B) The result shows the percentage of osteoblastic population of G0/G1, S, and G2/M cell cycle
phases, compared with the control. Each point of data represents the means of three replicate samples
± SEM. * = p < 0.05, ** = p < 0.01 when compared to the control.
3.3. Effects of Ps-GOS on Osteoblastic Differentiation of MC3T3-E1 Cells
Mineralization is the last stage of bone formation that results in the formation of calcified nodules
that contribute to bone strength [38]. To examine the effect of Ps-GOS, MC3T3-E1 cells were treated
with Ps-GOS for 14 and 21 days in an osteogenic induction medium to induce differentiation. Calcium
production inMC3T3-1 cells was determined by stainingwith Alizarin red S dye (Figure 3A). Extraction
and quantification of Alizarin red from treated cells showed that Ps-GOS significantly enhanced the
calcium deposit formation at both day 14 and 21, with the former time-point showing the maximal
increase (175%) when compared to control (Figure 3B) at 1 and 10 µg/mL Ps-GOS. In addition, ALP a
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marker of mature osteoblastic differentiation [39] was determined at day 14. All Ps-GOS treatments
markedly promoted ALP activity when compared to control (Figure 3C). This result also correlated
with the study of Yazid et al.: that the highest ALP level was produced from MC3T3-E1 cells at day
14 during osteoblast differentiation [40]. These results imply that Ps-GOS can promote osteoblast
differentiation and mineralization in the process of bone formation.
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Figure 3. The effect of different concentrations of Ps-GOS on osteoblastic differentiation and
mineralization of MC3T3-E1 cells. (A) Cells were treated with Ps-GOS for 14 and 21 days for
observing the calcium accumulation measured by Alizarin red S staining. (B) Quantitative data of
mineralization process relate to the intensity of Alizarin red S stains extracted by cetylpyridinium
chloride. (C) Alkaline phosphatase (ALP) activity of MC3T3-E1 cells after treatment with Ps-GOS for
14 days. Each point of data represents the means of four replicate samples ± SEM. The data in columns
with different letters in each group were significantly different at p < 0.05.
3.4. Ps-GOS Up-Regulated Osteogenic-Related Gene Marker Expression in MC3T3-E1 Cells
During osteoblast differentiation, many osteogenic gene markers are expressed; these genes
play important roles in matrix formation and calcium accumulation during bone formation. We
determined the expression levels of OPN, ALP, COL1, OCN, RUNX2, and BMP-2, in MC3T3-E1 cells,
after treating with Ps-GOS for 24 and 72 h using qRT-PCR. The results shown in Figure 4 indicate that
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the expression of ALP, COL1, OCN, and RUNX2 were up to two times higher than control levels after
24 h exposure to Ps-GOS. Moreover, Ps-GOS at concentrations of 0.1 and 1.0 µg/mL sharply enhanced
BMP-2 expression at 24 and 72 h, respectively. These results are consistent with the notion that Ps-GOS
promotes osteoblastic differentiation by upregulating osteogenic-related gene expression via the BMP
signaling pathway.
	
 )=
+5	 
D1 E%
'D1 
**P"9	
E!'+	
+5>+	
%,



 
'D1  	 
 


  	"
" "
' "
	
%
E!
"
"	


	!
 8
 0
  830 % 	
  $< $'< '$, , 1:<=>  
L

%'
	

.!68/E62,2'7

'D1 

%

+5>+,

		


  	
   O 7E ,  
  
 
  
  "	 

"


W**@
&*
 $	
$

(!!"%.
,E!
"
"	
	



"	'"

  # 	
 E!'+  8+ F  	   %  
'D1  	

 
 
E!'+8+830	
 .
"5/: 
 
	
 	
  E!'+  8+   %
  
  
  
'D1 

'D1 
	*P"95?
%%E!'+
"   

 
 .F/ 
	 .
" @0/     :

".
"@/X

%
E!'+

".
"@0/
"

** *  * P"9 
'D1     

  
"

 
 
 E!'+ 	

%


"	.
"@/ 


"

 
'D1   
"

  	
 	
 %  E!'+   + 


 

J*P"9.
"@6
6


8
Figure 4. Analysis of mRNA level expressions of OPN, OCN, COL1, ALP, RUNX2, and BMP-2 by
quantitative real-time polymerase chain reaction (PCR). MC3T3-E1 cells were treated with Ps-GOS in
various concentrations for 24 and 72 h. The data were obtained from three independent experiments
in four replicates as mean ± SEM. The data in columns with different letters in each group were
significantly different at p < 0.05.
3.5. Ps-GOS Stimulates Osteoblast Differentiation via BMP Signaling Pathway
The BMP signaling pathway is responsible for osteoblast differentiation through up-regulation
of the key proteins BMP-2 and Runx2. In the present study, we observed that Ps-GOS exposure
resulted in an increase in BMP-2 and Runx2 mRNA expression (Figure 4). We thus examined the
protein expression of BMP-2 and Runx2 to further validate the mechanism of action of Ps-GOS. Ps-GOS
treatment at concentrations up to 10 µg/mL for 48 h resulted in elevated levels of BMP-2, as judged
by both indirect immunofluorescence (IF) microscopy (Figure 5A), as well as by Western blotting
(Figure 5D). Quantitative analysis of BMP-2 staining (Figure 5A), following treatment with 0.01, 0.1,
and 10 µg/mL Ps-GOS for two days, indicated a significant increase in BMP-2 positive staining cells
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compared to the control (Figure 5B). Similarly, western blotting analysis showed that all Ps-GOS
treatments significantly enhanced protein expression level of BMP-2 at day 2, with maximal increase at
concentrations >0.1 µg/mL (Figure 5C). Consistent with the notion that Runx operates downstream of
BMP-2, Western blotting of Runx l showed that levels of this protein were significantly elevated after
exposure for 10 days to Ps-GOS concentrations > 0.1 µg/mL (Figure 5D).
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Figure 5. Effect of Ps-GOS on the bone morphogenetic protein (BMP) signaling pathway in osteoblast
cells. OsteoblasticMC3T-E1 cells were treatedwith various concentrations of Ps-GOS for 2 days. (A) The
image of BMP-2 expressing cells observed by immunofluorescence staining (original magnifications
20×). (B) Quantitation of immunofluorescence staining. (C) Protein level expression of BMP-2 was
determined by Western blot analysis at day 2. (D) Protein level expression of Runx2 at day 10. The
quantitation was calculated according to the referent bands of β-actin (C) and nucleolin (D). The data
were obtained from four replicates as mean ± SEM. The data in columns with different letters in each
group were significantly different at p < 0.05.
3.6. Stimulating Effect on Osteoblastic Differentiation by Ps-GOS Could Affect through MAPK and
Wnt/β-Catenin Signaling Pathways
While BMP signaling plays a critical role in osteoblast differentiation and bone formation,
additional pathways, participating in a range of cross-talk signaling, are also involved. The expression
of a range of MAPK family members was investigated by qRT-PCR. As shown in Figure 6, Ps-GOS
significantly promoted the expression of ERK1, ERK2, JNK1, and JNK2 following 12 and 24 h exposure,
compared to control, and in all cases, expression levels reverted to control levels or below after
48 h. A similar pattern was observed with p38α, although Ps-GOS-enhanced expression was reduced
after 48 h exposure and did not revert to control levels. We also investigated expression of genes
involved in Wnt/β-catenin signaling (Figure 7). Wnt5a, Fzd4, β-catenin, and LRP5were significantly
up-regulated with Ps-GOS after 12 and 24 h exposure, and expression levels then slightly decreased
at 48 h (the same time observed with MAPK). These outcomes suggest that the stimulatory effect of
Ps-GOS on osteoblastic differentiation additionally involves stimulation via MAPK and Wnt/β-catenin
signaling pathways.
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Figure 6. Analysis of mRNA level expressions of MAPK pathway genes ERK1, ERK2, JNK1, JNK2, and
p38α by quantitative real-time PCR.MC3T3-E1 cells were treated with Ps-GOS in various concentrations
for 24, 48, and 72 h. The data were obtained from three independent experiments in four replicates as
mean ± SEM. The data in columns with different letters in each group were significantly different at
p < 0.05.
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Figure 7. Analysis of mRNA level expressions of Wnt/β-catenin signaling pathway genes LRP5,
β-catenin,Wnt5a, and fzd4 by quantitative real-time PCR. MC3T3-E1 cells were treated with Ps-GOS in
various concentrations for 24, 48, and 72 h. The data were obtained from three independent experiments
in four replicates as mean ± SEM. The data in columns with different letters in each group were
significantly different at p < 0.05.
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4. Discussion
It is well known that osteoblasts are critical players in the regulation of bone formation and
bone remodeling. The reduction of osteoblast activity results in low bone mass and osteoporosis.
Recently, it has been shown that β-glucan has a therapeutic effect on osteoporosis by promoting the
function of osteoblasts. Lee at al. have suggested that β-(1-3),(1-6)-glucan has a stimulatory effect
on BMP-7 promoting bone formation by inducing the production of ALP and calcium accumulation
on mineralization [26]. However, the mechanism by which small molecular mass β-glucans, such as
Ps-GOS, promote bone formation has not yet been determined.
This study has demonstrated that Ps-GOS has the potential to prevent osteoporosis. At low
concentrations (<10 µg/mL), Ps-GOS induced osteoblastic proliferation in MC3T3-E1 cells without
toxicity for up to 48 h of treatment. The elevated rate of proliferation correlated with an increase in the
proportion of cells in S-phase, suggesting that Ps-GOS promotes proliferation by stimulating the G1-S
transition within the cell cycle.
TheproductionofALPand calciumaccumulation are essential steps in theprocess ofmineralization
leading to bone formation. ALP, a marker of early-stage osteoblastic differentiation, can be detected
on the cell surface and in matrix vesicles of mature osteoblasts [41]. High level expression of ALP
initiates and plays a fundamental role during the process of mineralization process [42], where it has
been suggested that it hydrolyses pyrophosphate, a natural inhibitor of mineralization, concomitantly
increasing local phosphate concentration [43,44]. We found that Ps-GOS stimulated the expression
of ALP and promoted the accumulation of calcium, consistent with a potential role for Ps-GOS in
promoting bone formation.
In normal development, mesenchymal stem cells function as progenitors of osteoblasts and
osteocytes, as well as adipocytes and myocytes [45]. Differentiation of stem cells into an osteoblast
lineage requires specific osteogenic signaling proteins and transcription factors. BMP-2, a member of
the transforming growth factor-beta (TGF-β) superfamily, is synthesized by osteoblasts and is a critical
inducer regulating osteoblastic differentiation and bone formation [46]. BMP-2-induced osteogenesis
is absolutely dependent on the formation and transcriptional activity of the downstream osteogenic
complex Runx2-SMAD. Runx2 has been reported to mediate the expression of many osteogenic gene
markers, including ALP, COL1, OCN, and OPN [47]. Mutations on one allele of human Runx2 gene
cause cleidocranial dysplasia [48], while deletion of Runx2 in mice leads to a complete failure of bone
formation and ossification [49]. We found that Ps-GOS promoted bone formation by upregulating both
gene and protein expression levels of BMP-2 and Runx2. As a consequence of Runx2 up-regulation,
Ps-GOS also promoted expression of ALP, COL1, and OCN. Surprisingly, Ps-GOS had no effect on OPN
expression. The significance of this observation is not yet clear.
The Wnt/β-catenin signaling pathway works cooperatively with BMP signaling to regulate
osteoblast differentiation and bone formation. Crosstalk between Wnt/β-catenin and BMP signaling
pathways results in an elevation in BMP-2 and Runx2 expression; the target of this signaling in
osteoblasts [50]. Wnt/β-catenin signaling is activated when Wnt ligand binds to the receptors Frizzled
(Fzd) and low-density lipoprotein receptor-related protein 5 or 6 (LRP5/6), which in turn inhibits
β-catenin phosphorylation. The translocation of β-catenin into nucleus leads to the activation of
members of the TCF/LEF transcription factor family in order to promote osteogenic gene expression [51].
Mutation of LRP5 can cause osteoporosis pseudoglioma syndrome (OPPG) in humans [52] and decrease
osteoblast numbers in mice [53]. In addition, Wnt5a is an important component in the regulation of
Wnt/β-catenin signaling in osteoblast linear cells, as lack of Wnt5a leads to a reduction in LRP5 and
LRP6 expression [54]. To identify additional molecular targets of Ps-GOS that might be associated with
the up-regulation of BMP-2 and Runx2, we examined expression levels of Wnt/β-catenin-related genes.
Our data reveled that Ps-GOS significantly up-regulates the expression of Wnt5a, LRP5, β-catenin,
and Fzd4 mRNA, in MC3T3-E1 cells, suggesting that Ps-GOS may prevent bone loss in osteoporosis
through Wnt/β-catenin together with BMP-2 signaling pathways.
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The JNK-ERK-p38 MAPK signaling pathways also play an essential role in the control of bone
formation and bone homeostasis during osteoblast differentiation [55]. Specifically, JNK is important
for late-stage osteoblast differentiation, as inactivation of JNK by a specific small molecule inhibitor
causes a lack of mineralization in MC3T3-E1 cells [56], while deletion of JNK1 and JNK2 in mice
(Jnk1-2osx) results in severe osteopenia arising from bone loss [57]. Phosphorylation and consequent
activation of Runx2 in osteoblasts is dependent on the expression of both ERK1 and ERK2 [58], while
inactivation of ERK1 and ERK2 reduces β-catenin expression [59]. In addition, p38 is required for
early-stage of osteoblast differentiation by promoting osteogenic differentiation markers, including
ALP, osteocalcin, and mineralization [60].
In summary, this study demonstrated for the first time that the short-chain-length,
lower-molecular-weight, higher-water-solubility Pleurotus sajor-caju glucanoligosaccharide (Ps-GOS)
promotes osteoblast differentiation and mineralization, which are accompanied by the increase of
ALP, COL1, and OCN expression through the induction of BMP-2 and Runx2. Furthermore, we have
found that Ps-GOS also promotes bone formation via Wnt/β-catenin and MAPK signaling pathways.
Thus, our findings show that Ps-GOS could be developed as a candidate supplement promoting bone
formation. As such, this represents an example of both value creation as well as value addition in the
biotechnological exploitation and use of natural rubber latex serum. Future work will be directed at
determining the precise mechanism of action of Ps-GOS for comparison with other known modulators
of osteoblastogenesis. Given the important role of the RANKL/RANL/OPG system in regulating
osteoclast function, it will be iintersting to establish whether Ps-GOS can impact this system also.
5. Conclusions
In the present study, we report for the first time that small size Pleurotus sajor-caju
glucanoligosaccharide (Ps-GOS) has a stimulatory effect, promoting bone formation by stimulating
osteoblast proliferation, differentiation, and mineralization possibility through BMP-2, Wnt/β-catenin,
and MAPK signaling pathways. Ps-GOS has potential as a useful therapeutic drug to
prevent osteoporosis.
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